Prothena Corporation plc
PRTAProthena is a late-stage clinical biotechnology company specializing in protein dysregulation to treat neurodegenerative and rare peripheral amyloid diseases.
Table of contents
Earnings
Next report
Aug 3, 2026 (In 5 days)Competitors
By market cap
By revenue growth
Profile
Prothena is a late-stage clinical biotechnology company specializing in protein dysregulation to treat neurodegenerative and rare peripheral amyloid diseases. The company leverages deep scientific expertise to develop therapeutic candidates that target misfolded proteins associated with conditions like Parkinson’s and Alzheimer’s. Its value proposition centers on a hybrid model of advancing a wholly-owned internal pipeline alongside high-value strategic partnerships with global pharmaceutical leaders.
A late-stage clinical player with a validated platform evidenced by multiple active Phase 2 and Phase 3 programs partnered with industry leaders.
Questions, answered.
- What is Prothena Corporation plc's market cap?
- Prothena Corporation plc (PRTA) has a market capitalization of $455.5M and trades on NASDAQ.
- Who are Prothena Corporation plc's competitors?
- Prothena Corporation plc's key competitors include Alnylam Pharmaceuticals, ProMIS Neurosciences Inc. Common Shares (ON), Gain Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Prothena Corporation plc partner with?
- Prothena Corporation plc's notable partners include Roche, Novo Nordisk, Bristol Myers Squibb, and others.
- Where is Prothena Corporation plc headquartered?
- Prothena Corporation plc is headquartered in Ireland and employs approximately 173 people. It has been publicly traded since 2012.